Depression

A new study showed zuranolone treatment in patients with major depressive disorder demonstrates a rapid and statistically significant reduction in depressive symptoms.

Treatment decisions lie on a continuum—befitting a dimensional approach to diagnosis.

How does treatment for self-blaming depression differ from treatment of other types of depression?

Exploring cognitive biases toward the DSM and their avoidable effects on treatment decisions.

What do these have to do with CBT, creative visualization, and contemporary psychiatry?

Associated outcomes include higher rates of psychiatric hospitalization and mortality.

Sleep, depression, and bipolar disorder: what's the connection?

Effective treatment of depression in individuals with comorbid depression and type 2 diabetes mellitus is important for both conditions.

May his words and ideals continue to inspire...

The FDA has given Investigational New Drug clearance for a clinical drug-drug interaction study of R-ketamine (PCN-101).

Here’s how to help patients see the light when faced with the winter blues.

The glass is half full: reflections on where we are and hope for where we are heading in psychiatry.

Study also suggests link between postpartum depression and insomnia.

Psychiatric Times featured a wide variety of psychiatric issues in this year’s CMEs.

Research identifies common reasons and coping mechanisms for depression that increases during the holidays.

Caplyta is now FDA-approved for depressive episodes from bipolar I and II.

Data from a clinical program evaluating the efficacy and safety of zuranolone was presented at the American College of Neuropsychopharmacology Congress. What new developments did they share?

Research also shows increased prevalence of social risks and unmet social needs.

How can transcranial magnetic stimulation help patients with treatment-resistant depression?

Treatment-resistant depression: how to diagnose, what treatment options are available, and how to best help patients.

What is the connection between inflammation and mood disorders?

How can we improve treatment response? Look to the patient.

Loss and suffering can be hard for both patient and provider. Here’s what we know, what we need to learn, and how to protect yourself as a clinician.

What's new and noteworthy in children and adolescent psychiatry?

Results suggest that psilocybin therapy may prove to be helpful in improving quality of life for patients with cancer.